JP2022500387A - Ｍｕｓｋ阻害 - Google Patents

Ｍｕｓｋ阻害 Download PDF

Info

Publication number
JP2022500387A
JP2022500387A JP2021513331A JP2021513331A JP2022500387A JP 2022500387 A JP2022500387 A JP 2022500387A JP 2021513331 A JP2021513331 A JP 2021513331A JP 2021513331 A JP2021513331 A JP 2021513331A JP 2022500387 A JP2022500387 A JP 2022500387A
Authority
JP
Japan
Prior art keywords
seq
binding
antibody
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021513331A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020055240A5 (https=
JP2022500387A5 (https=
Inventor
シルヴェル・マリア・ファン・デル・マーレル
ヨハンネス・ユストゥス・ヘーラルト・マリア・フェルシューレン
マルティナ・フェラルディナ・マリア・ハイベルス
ヤーコブ・ヤン・プロンプ
Original Assignee
アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL2021589A external-priority patent/NL2021589B1/en
Application filed by アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム filed Critical アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム
Publication of JP2022500387A publication Critical patent/JP2022500387A/ja
Publication of JPWO2020055240A5 publication Critical patent/JPWO2020055240A5/ja
Publication of JP2022500387A5 publication Critical patent/JP2022500387A5/ja
Priority to JP2024191894A priority Critical patent/JP2025016653A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021513331A 2018-09-10 2019-09-05 Ｍｕｓｋ阻害 Pending JP2022500387A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024191894A JP2025016653A (ja) 2018-09-10 2024-10-31 Ｍｕｓｋ阻害

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2021589A NL2021589B1 (en) 2018-09-10 2018-09-10 MuSK inhibition
NL2021589 2018-09-10
NL2023119 2019-05-13
NL2023119 2019-05-13
PCT/NL2019/050576 WO2020055240A1 (en) 2018-09-10 2019-09-05 Musk inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024191894A Division JP2025016653A (ja) 2018-09-10 2024-10-31 Ｍｕｓｋ阻害

Publications (3)

Publication Number Publication Date
JP2022500387A true JP2022500387A (ja) 2022-01-04
JPWO2020055240A5 JPWO2020055240A5 (https=) 2022-09-14
JP2022500387A5 JP2022500387A5 (https=) 2022-09-14

Family

ID=68138766

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513331A Pending JP2022500387A (ja) 2018-09-10 2019-09-05 Ｍｕｓｋ阻害
JP2024191894A Pending JP2025016653A (ja) 2018-09-10 2024-10-31 Ｍｕｓｋ阻害

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024191894A Pending JP2025016653A (ja) 2018-09-10 2024-10-31 Ｍｕｓｋ阻害

Country Status (8)

Country Link
US (1) US20220002438A1 (https=)
EP (1) EP3850014A1 (https=)
JP (2) JP2022500387A (https=)
CN (1) CN113614112A (https=)
AU (1) AU2019337338A1 (https=)
CA (1) CA3112288A1 (https=)
IL (1) IL281409A (https=)
WO (1) WO2020055240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114487448B (zh) * 2022-01-21 2022-10-18 天津天海新域生物科技有限公司 用于检测重症肌无力相关抗体的组合物、试剂盒及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) * 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
WO2015039015A2 (en) * 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US7759314B2 (en) * 2001-08-15 2010-07-20 Brown University Treatment of muscular dystrophies and related disorders
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7807378B2 (en) * 2005-12-29 2010-10-05 Industrial Technology Research Institute (Itri) Method of diagnosing myasthenia gravis and kits therefor
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
JP7023840B2 (ja) * 2015-10-07 2022-02-22 メモリアル スローン ケタリング キャンサー センター 神経筋接合活性のモジュレーターを同定するｉｎ ｖｉｔｒｏの方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011207769A (ja) * 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) * 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
WO2015039015A2 (en) * 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DRUG DELIV. SYS., vol. 28(5), JPN6024021999, 2013, pages 412 - 423, ISSN: 0005477968 *
IMMUNOLOGY TODAY, vol. 14, no. 6, JPN6024036638, 1993, pages 243 - 246, ISSN: 0005477971 *
J. AUTOIMMUN., vol. 77, JPN6023036745, 2017, pages 104 - 115, ISSN: 0005477966 *
J. MOL. BIOL., vol. 224, JPN6024036637, 1992, pages 487 - 499, ISSN: 0005477970 *
J. NEUROIMMUNOL., vol. Vol.244 No.1-2, JPN6023036746, 2012, pages 1 - 7, ISSN: 0005148475 *
PROC. NATL. ACAD. SCI. U.S.A., vol. 110, no. 51, JPN6023036744, 2013, pages 20783 - 20788, ISSN: 0005477965 *
日本結晶学会誌, vol. 37, JPN6024036636, 1995, pages 134 - 136, ISSN: 0005477969 *
神経治療, vol. 30, no. 4, JPN6024025020, 2013, pages 471 - 494, ISSN: 0005477967 *

Also Published As

Publication number Publication date
CA3112288A1 (en) 2020-03-19
JP2025016653A (ja) 2025-02-04
EP3850014A1 (en) 2021-07-21
AU2019337338A1 (en) 2021-04-08
US20220002438A1 (en) 2022-01-06
WO2020055240A1 (en) 2020-03-19
CN113614112A (zh) 2021-11-05
IL281409A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
KR101999872B1 (ko) 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
KR20190083356A (ko) 시누클레인병증의 치료를 위한 제제, 용도 및 방법
JP7438937B2 (ja) 抗ｔｒｋｂモノクローナル抗体および使用の方法
RS58439B1 (sr) Anti-asic1 antitela i njihove upotrebe
JP2021521881A (ja) 神経成長因子に対するモノクローナル抗体、並びにそれをコードする遺伝子及びその使用
KR20170082631A (ko) 뇌졸중의 치료 또는 예방 방법
KR20260013489A (ko) TrkA 항체 및 이의 용도
KR20210032412A (ko) 말초신경장애, 또는 말초신경장애 혹은 성상세포장애가 인정되는 질환에 따른 동통의 예방 또는 치료 방법
US20250084173A1 (en) TrkA ANTIBODY AND APPLICATION THEREOF
JP2025016653A (ja) Ｍｕｓｋ阻害
US20240043562A1 (en) Musk activation
NL2021591B1 (en) MuSK activation
NL2021589B1 (en) MuSK inhibition
CN117903313B (zh) 一种抗iars抗体及其应用
RU2847366C1 (ru) Профилактический или терапевтический агент для лечения деменции
KR20240015200A (ko) 뇌신경계 질환 치료하기 위한 병용투여용 항체 및 이를 포함하는 약학조성물
RU2809500C2 (ru) СВЯЗЫВАЮЩИЙ RGMa БЕЛОК И ЕГО ИСПОЛЬЗОВАНИЕ
WO2026044246A1 (en) Anti-cadherin-17 antibodies and use thereof
KR20240015800A (ko) 뇌신경계 질환을 치료하기 위하여 혈관뇌장벽을 통과할 수 있는 이중특이적 항체와 결합체
CN121226559A (zh) 双特异性抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241108

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241206